Shanghai Pharmaceutical (usa) Inc. - Net Worth and Insider Trading

Shanghai Pharmaceutical (usa) Inc. Net Worth

The estimated net worth of Shanghai Pharmaceutical (usa) Inc. is at least $2 Million dollars as of 2024-05-03. Shanghai Pharmaceutical (usa) Inc. is the 10% Owner of Oncternal Therapeutics Inc and owns about 177,222 shares of Oncternal Therapeutics Inc (ONCT) stock worth over $2 Million. Details can be seen in Shanghai Pharmaceutical (usa) Inc.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Shanghai Pharmaceutical (usa) Inc. has not made any transactions after 2020-07-21 and currently still holds the listed stock(s).

Transaction Summary of Shanghai Pharmaceutical (usa) Inc.

To

Shanghai Pharmaceutical (usa) Inc. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Shanghai Pharmaceutical (usa) Inc. owns 1 companies in total, including Oncternal Therapeutics Inc (ONCT) .

Click here to see the complete history of Shanghai Pharmaceutical (usa) Inc.’s form 4 insider trades.

Insider Ownership Summary of Shanghai Pharmaceutical (usa) Inc.

Ticker Comapny Transaction Date Type of Owner
ONCT Oncternal Therapeutics Inc 2020-07-21 10 percent owner

Shanghai Pharmaceutical (usa) Inc. Latest Holdings Summary

Shanghai Pharmaceutical (usa) Inc. currently owns a total of 1 stock. Shanghai Pharmaceutical (usa) Inc. owns 177,222 shares of Oncternal Therapeutics Inc (ONCT) as of July 21, 2020, with a value of $2 Million.

Latest Holdings of Shanghai Pharmaceutical (usa) Inc.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ONCT Oncternal Therapeutics Inc 2020-07-21 177,222 8.75 1,549,806

Holding Weightings of Shanghai Pharmaceutical (usa) Inc.


Shanghai Pharmaceutical (usa) Inc. Form 4 Trading Tracker

According to the SEC Form 4 filings, Shanghai Pharmaceutical (usa) Inc. has made a total of 1 transactions in Oncternal Therapeutics Inc (ONCT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Oncternal Therapeutics Inc is the acquisition of 52,466 shares on July 21, 2020, which cost Shanghai Pharmaceutical (usa) Inc. around $2 Million.

Insider Trading History of Shanghai Pharmaceutical (usa) Inc.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Shanghai Pharmaceutical (usa) Inc. Trading Performance

GuruFocus tracks the stock performance after each of Shanghai Pharmaceutical (usa) Inc.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Shanghai Pharmaceutical (usa) Inc. is -34.25%. GuruFocus also compares Shanghai Pharmaceutical (usa) Inc.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Shanghai Pharmaceutical (usa) Inc. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Shanghai Pharmaceutical (usa) Inc.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Shanghai Pharmaceutical (usa) Inc.

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 5.91
Relative Return to S&P 500(%) 1.62

Shanghai Pharmaceutical (usa) Inc. Ownership Network

Ownership Network List of Shanghai Pharmaceutical (usa) Inc.

No Data

Ownership Network Relation of Shanghai Pharmaceutical (usa) Inc.


Shanghai Pharmaceutical (usa) Inc. Owned Company Details

What does Oncternal Therapeutics Inc do?

Who are the key executives at Oncternal Therapeutics Inc?

Shanghai Pharmaceutical (usa) Inc. is the 10 percent owner of Oncternal Therapeutics Inc. Other key executives at Oncternal Therapeutics Inc include director & Executive Chairman Robert James Wills , Chief Scientific Officer Gunnar F. Kaufmann , and Chief Medical Officer Salim Yazji .

Oncternal Therapeutics Inc (ONCT) Insider Trades Summary

Over the past 18 months, Shanghai Pharmaceutical (usa) Inc. made no insider transaction in Oncternal Therapeutics Inc (ONCT). Other recent insider transactions involving Oncternal Therapeutics Inc (ONCT) include a net purchase of 9,020 shares made by Robert James Wills , a net purchase of 150,000 shares made by James B Breitmeyer , and a net purchase of 30,000 shares made by Richard G Vincent .

In summary, during the past 3 months, insiders sold 980 shares of Oncternal Therapeutics Inc (ONCT) in total and bought 10,980 shares, with a net purchase of 10,000 shares. During the past 18 months, 980 shares of Oncternal Therapeutics Inc (ONCT) were sold and 23,880 shares were bought by its insiders, resulting in a net purchase of 22,900 shares.

Oncternal Therapeutics Inc (ONCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Oncternal Therapeutics Inc Insider Transactions

No Available Data

Shanghai Pharmaceutical (usa) Inc. Mailing Address

Above is the net worth, insider trading, and ownership report for Shanghai Pharmaceutical (usa) Inc.. You might contact Shanghai Pharmaceutical (usa) Inc. via mailing address: C/o Oncternal Therapeutics, Inc., 3525 Del Mar Heights Road #821, San Diego Ca 92130-2122.

Discussions on Shanghai Pharmaceutical (usa) Inc.

No discussions yet.